BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu C, Wang Z, Sun Z, Zhang L, Zhang W, Xu Y, Zhang JJ. Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives. J Med Chem 2020;63:13397-412. [PMID: 32813515 DOI: 10.1021/acs.jmedchem.0c00950] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Biancalana L, Kostrhunova H, Batchelor LK, Hadiji M, Degano I, Pampaloni G, Zacchini S, Dyson PJ, Brabec V, Marchetti F. Hetero-Bis-Conjugation of Bioactive Molecules to Half-Sandwich Ruthenium(II) and Iridium(III) Complexes Provides Synergic Effects in Cancer Cell Cytotoxicity. Inorg Chem 2021;60:9529-41. [PMID: 34156246 DOI: 10.1021/acs.inorgchem.1c00641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Peng K, Liang B, Liu W, Mao Z. What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives. Coordination Chemistry Reviews 2021;449:214210. [DOI: 10.1016/j.ccr.2021.214210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kacsir I, Sipos A, Ujlaki G, Buglyó P, Somsák L, Bai P, Bokor É. Ruthenium Half-Sandwich Type Complexes with Bidentate Monosaccharide Ligands Show Antineoplastic Activity in Ovarian Cancer Cell Models through Reactive Oxygen Species Production. Int J Mol Sci 2021;22:10454. [PMID: 34638791 DOI: 10.3390/ijms221910454] [Reference Citation Analysis]
4 Dong J, Zhu D, Chen M, Wang T, Gao Y, Liu W. Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function. Thoracic Cancer. [DOI: 10.1111/1759-7714.14425] [Reference Citation Analysis]
5 Liu J, Zou T, Yin J, Wang Z, Liu C, Huang H, Ding F, Lei M, Wang Y, Liu M, Liu Z, Tan L, Chen J. Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients With Lung Cancer. Front Pharmacol 2022;13:915822. [DOI: 10.3389/fphar.2022.915822] [Reference Citation Analysis]
6 Wang D, Feng W, Wang X, Lin D, Wang X, Guo X, Miao Q, Ma J, Xia G. Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle. Eur J Pharm Sci 2021;167:106000. [PMID: 34517105 DOI: 10.1016/j.ejps.2021.106000] [Reference Citation Analysis]
7 Zhang W, Du XF, Liu B, Li C, Long J, Zhao MX, Yao Z, Liang XJ, Lai Y. Engineering Supramolecular Nanomedicine for Targeted Near Infrared-triggered Mitochondrial Dysfunction to Potentiate Cisplatin for Efficient Chemophototherapy. ACS Nano 2021. [PMID: 34962119 DOI: 10.1021/acsnano.1c09555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Cai Z, Teng Y, Chen Y. The Effect of Shenyi Capsule on Non-Small-Cell Lung Cancer Combined with Chemotherapy from the Yin-Yang Perspective. Evid Based Complement Alternat Med 2021;2021:1653750. [PMID: 34512772 DOI: 10.1155/2021/1653750] [Reference Citation Analysis]
9 Peña Q, Wang A, Zaremba O, Shi Y, Scheeren HW, Metselaar JM, Kiessling F, Pallares RM, Wuttke S, Lammers T. Metallodrugs in cancer nanomedicine. Chem Soc Rev 2022. [PMID: 35262108 DOI: 10.1039/d1cs00468a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Han W, He W, Song Y, Zhao J, Song Z, Shan Y, Hua W, Sun Y. Multifunctional platinum(IV) complex bearing HDAC inhibitor and biotin moiety exhibits prominent cytotoxicity and tumor-targeting ability. Dalton Trans 2022;51:7343-51. [PMID: 35466968 DOI: 10.1039/d2dt00090c] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sun R, Du C, Li J, Zhou Y, Xiong W, Xiang J, Liu J, Xiao Z, Fang L, Li Z. Systematic Investigation of DNA Methylation Associated With Platinum Chemotherapy Resistance Across 13 Cancer Types. Front Pharmacol 2021;12:616529. [PMID: 33995018 DOI: 10.3389/fphar.2021.616529] [Reference Citation Analysis]
12 Braccini S, Rizzi G, Biancalana L, Pratesi A, Zacchini S, Pampaloni G, Chiellini F, Marchetti F. Anticancer Diiron Vinyliminium Complexes: A Structure-Activity Relationship Study. Pharmaceutics 2021;13:1158. [PMID: 34452119 DOI: 10.3390/pharmaceutics13081158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Famurewa AC, Mukherjee AG, Wanjari UR, Sukumar A, Murali R, Renu K, Vellingiri B, Dey A, Valsala Gopalakrishnan A. Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs. Life Sci 2022;305:120789. [PMID: 35817170 DOI: 10.1016/j.lfs.2022.120789] [Reference Citation Analysis]
14 Kacsir I, Sipos A, Bényei A, Janka E, Buglyó P, Somsák L, Bai P, Bokor É. Reactive Oxygen Species Production Is Responsible for Antineoplastic Activity of Osmium, Ruthenium, Iridium and Rhodium Half-Sandwich Type Complexes with Bidentate Glycosyl Heterocyclic Ligands in Various Cancer Cell Models. Int J Mol Sci 2022;23:813. [PMID: 35054999 DOI: 10.3390/ijms23020813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lang T, Li N, Zhang J, Li Y, Rong R, Fu Y. Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro. Drug Deliv 2021;28:1272-80. [PMID: 34176381 DOI: 10.1080/10717544.2021.1938754] [Reference Citation Analysis]
16 Schoch S, Braccini S, Biancalana L, Pratesi A, Funaioli T, Zacchini S, Pampaloni G, Chiellini F, Marchetti F. When ferrocene and diiron organometallics meet: triiron vinyliminium complexes exhibit strong cytotoxicity and cancer cell selectivity. Inorg Chem Front . [DOI: 10.1039/d2qi00534d] [Reference Citation Analysis]